Official journal of the Slovak Society of Cardiology,
Slovak Society of Hypertension and Slovak Association for Cardiac Arrhythmias

Cardiology Letters 2020, 29(3):131-134

Comment on 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias

Pella D
II. kardiologická klinika UPJŠ LF a VÚSCH, a. s. Košice, Slovenská republika

Published: March 1, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pella D. Comment on 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias. Cardiology Letters. 2020;29(3):131-134.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees.ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-1818.
    2. Catapano AL, Graham I, De Backer G, et al. Authors/Task Force Members; Additional Contributor. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016;37:2999-3058. Go to original source...
    3. Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2019 ESC/ EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140-205. Go to original source...
    4. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017;38:2459-2472. Go to original source...
    5. Battaggia A, Scalisi A, Donzelli A. The systematic review of randomized controlled trials of PCSK9 antibodies challenges their "efficacy breakthrough" and the "lower, the better" theory. Curr Med Res Opin 2018;34: 1725-1730. Go to original source...
    6. Sabatine MS, Giugliano RP, Keech AC, et al. FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713-1722. Go to original source...
    7. Schwartz GG, Steg PG, Szarek M, ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018;379:2097-2107. Go to original source...
    8. Wong ND, Shapiro MD. Interpreting the Findings From the Recent PCSK9 Monoclonal Antibody Cardiovascular Outcomes Trials. Front Cardiovasc Med 2019;6:14. Published online 2019 Mar 6. doi: 10.3389/fcvm.2019.00014. Go to original source...
    9. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Eng J Med 2015;372:2387-2397. Go to original source...
    10. Banach M, Rizzo M, Toth PP, et al. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci 2015;11:1-23. Go to original source...
    11. Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med 2017;376:1430-1440. Go to original source...
    12. Saeed A, Ballantyne CM. Bempedoic acid (ETC-1002): a current review. Cardiol Clin 2018;36:257-264. Go to original source...
    13. Bhatt DL, Steg PG, Miller M, REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019;380:11-22. Go to original source...

    Return to the content